Over $1.45 Billion Flows into Innovation as Investors Bet on Transformative Solutions

In a significant demonstration of confidence in healthcare innovation, investors poured over $1.45 billion into the sector this week, backing technologies that promise to reshape patient care across multiple fronts. The funding landscape reveals a strategic shift toward artificial intelligence applications and highly specialized care models that target underserved health conditions.

FUNDING

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a Cambridge, MA-based precision genetic medicine for rare diseases company, raised $600M in a senior secured revolving facility with a bank syndicate. JPMorgan Chase Bank, N.A. served as Administrative Agent, Lead Arranger, and Joint Bookrunner. The syndicate also included Barclays Bank PLC, Citizens Bank, N.A., Goldman Sachs USA, Morgan Stanley Senior Funding, Inc., Royal Bank of Canada, Fifth Third Bank, National Association, UBS AG, Stamford Branch, and Bank of America.

Abridge, San Francisco, CA-based provider of a generative AI platform for clinical conversations, raised $250M in Series D funding. Elad Gil and IVP co-led the round, which included participation from Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health Ventures, K. Ventures, Lightspeed, nVentures, Redpoint, Spark Capital, and SV Angel.

OrganOx, an Oxford, UK-based organ medical technology company, raised $142M in equity funding. The round was led by new investor HealthQuest Capital with participation from existing investors BGF and LAUXERA CAPITAL PARTNERS, along with additional new investors Sofina, Soleus Capital Management, L.P., and Avidity Partners. Existing investors included the University of Oxford, Technikos, the Oxford Technology and Innovations Fund, and Longwall Venture Partners LLP Ventures.

Bambusa Therapeutics, a Boston, MA-based biotechnology company, raised Series A financing?of approximately?$90M. The round was led by new investor RA Capital Management and joined by new investors,?including?Janus Henderson Investors, Redmile Group, The Invus Group, and ADAR1 Capital Management. All existing investors?also participated.

Spatial biology startup?Stellaromics Inc.?raises $80M to support commercializing its 3D sequencing platform for spatial multiomics. Catalyst4, a Silicon Valley nonprofit founded by Google co-founder Sergey Brin, led the funding round. Stanford University’s venture arm also participated. The technology enables high-resolution mapping of gene expression and cell clusters in intact tissue, analyzing slices 100 μm thick or more and tracking the spatial distribution of thousands of genes, with early adoption in neuroscience and cancer research.

Endovascular Engineering, a medical technology company for Pulmonary Embolism based in Menlo Park, CA, raised $42M in Series B financing. The round was co-led by?415 Capital?and?S3?Ventures, with participation from?Panakes Partners, M&L Healthcare, and Santé Ventures. Two global strategic investors made substantial commitments alongside Cordis, which continues its strategic partnership with the company.

Frontera, a Denver, CO-based company advancing health equity through AI-enabled autism care, raised $32M in Seed funding. The round was led by Lux Capital and Lightspeed, with participation from Bison Ventures, Menlo Ventures, and Inspired Capital.

EG 427 , a Paris, France-based biotechnology company for developing pinpoint genetic medicines for prevalent chronic diseases in neurology, raised €27M in Series B funding. The round was co-led by Andera Partners and Bpifrance, with participation from the InnoBio investment strategy.??

Atrandi Biosciences, a Vilnius, Lithuania-based life sciences company advancing new single-cell analysis technology, raised $25M in Series A funding. The round was led by Lux Capital, with participation from Vsquared Ventures, Practica Capital, Metaplanet, and GRIDS Capital.

Reverb Therapeutics, a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, is based in Vancouver, BC, Canada. The company raised $21M in Seed funding. Amplitude Ventures led the round, which included participation from myeloma investment fund, KdT Ventures, Finchley Healthcare Ventures, InBC Investment Corp. (InBC), and Seido Capital.

Avandra Imaging, a Cleveland, OH-based platform provider for federated networks for medical imaging and clinical data, raised $17.75M in funding. Aegis and SpringRock Ventures co-led the rounds. Memorial Hermann Health System and Northwell Health, founding members of the Aegis Digital Consortium, participated along with Kompass Ventures, Greater Ventures, Scott Gaines, and Dr. Mark Montoney.

Subsense Inc., a Palo Alto, CA-based neurotechnology company developing a non-surgical, nanoparticle-based Brain-Computer Interface (BCI), raised $17M in Seed funding. Golden Falcon Capital led the round.

Perceive Pharma, a San Francisco, CA-based pharmaceutical company advancing novel small molecule therapeutics in ophthalmology, raised $15M in Series A funding. Deerfield Management, Johnson & Johnson, Braidwell, GV (Google Ventures), the Retinal Degeneration Fund, and Catalio Capital Management led the round.

Cagent Vascular, a Wayne, PA-based developer of serration technology for vessel dilation in endovascular interventions, received $15M in growth capital from Trinity Capital (NASDAQ:?TRIN).

Posterity Health, a Denver, CO-based male reproductive and hormonal health company, raised $13M in Series A funding. The round was led by Georgetown Equity Partners, with participation from existing investors FCA Ventures, Distributed Ventures, and WVV Capital. New investors included SteelSky Ventures, Scrub Capital, and others. The company intends to use the funds to continue expanding its platform and reach, ensuring that every man can access high-quality reproductive care at every stage of life.

Millie, a tech-enabled maternity clinic based in San Francisco, CA, raised $12M in Series A funding. The round was led by TMV and Foreground Capital, with participation from Pivotal Ventures and the March of Dimes Innovation Fund, including Ingeborg Investments, alongside BBG Ventures, Joyance Partners, LearnStart, Amboy Street Ventures, Mother Ventures, Coyote Ventures, and Chai Ventures.

EnPlusOne Biosciences, a biotechnology company based in Watertown, MA, empowers enzymes to deliver RNA efficiently at scale. The company has secured $10 million in funding, led by?Northpond Ventures?and?Breakout Ventures.

Paradox Immunotherapeutics, a pharmaceutical company based in Toronto, Canada, that develops antibody therapies, received a $10M investment from Symbiosis Capital.

Berlin Heals Holding AG, a Zug, Switzerland-based late-stage MedTech startup, raised over CHF7M in funding. Backers were not disclosed. The company intends to use the funds to support first-in-human studies to evaluate the safety and efficacy of these new approaches and prepare for the large pivotal trial for global regulatory and reimbursement approvals.

Keebler Health, a Durham, NC-based developer of an AI-native risk adjustment platform for healthcare providers, raised $6M in Seed funding. The round, which brought the total amount to $7.8M, included participation from Freestyle Capital, MBX Capital, New Stack Ventures, Underdog Labs, Everywhere Ventures, Ludlow Ventures, ??Primordial Ventures, the Tweener Fund, the Hustle Fund, Deb Liu, and Bong Koh.

Variational AI, a Vancouver, BC, Canada-based developer of a foundation model for small-molecule drug discovery, raised $5.5M in Seed extension funding. Nimbus Synergies led the round, including Merck Global Health Innovation Fund, Quimby Investments, Threshold Impact, Defined Capital, and existing investors Flying Fish Partners, A&E Investment, LLC, and Nepenthe Capital.

Fuse Vectors, a Copenhagen, Denmark-based gene therapy company, raised $5.2M in Pre-Seed Funding. HCVC led the round.

VoiceCare AI, a San Francisco, CA-based healthcare administration general intelligence (HAGI) company, raised $3.85M in funding.?The round was led by Caduceus Capital Partners, LLC, with participation from Bread and Butter Ventures.

Proximity, a Chicago, IL-based provider of an automation platform optimizing 340B drug discount revenue for qualified healthcare providers, raised $3M in Seed funding. LRVHealth led the round?with participation from?Commonweal Ventures.

Stablepharma Limited, a London, UK-based biotechnology firm, received a €2.5M grant through the EIC Accelerator Program. Stablepharma has developed StablevaX?, the technology platform that transforms approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This innovation addresses the critical global challenge of distribution, storage, and wastage issues associated with temperature-sensitive products reliant on the cold chain.

Sonar, a Sacramento, CA-based provider of an AI-powered mental health platform for young people, raised $2.4M in funding. Nina Capital led the round, including participation from GSR Ventures and J4.Ventures and support from the Stanford University Social Impact Founder Fellowship.

Validose, a precision medication delivery company based in NYC, raised $2M in Pre-Seed funding. Peter Bauer’s Family Office led the round as part of its Technology for Humanity strategy.?10XBeta,?Interstate Fusion Ventures,?and Angel investors also participated.

Swell, a mental health company based in Louisville, KY, raised $1.6M in funding. Backers included Keyhorse Capital, Bluegrass Angels, PeakState Ventures, defy.vc, and Fairwater Labs. Swell is addressing the nationwide therapist shortage with scalable, AI-enabled self-guided care. It prioritizes underserved markets, including hyperlocal communities such as the military, to ensure that mental health resources are more accessible and impactful.

Monument Therapeutics, a neuroscience company based in Manchester, UK, applies digital biomarkers to psychiatric drug development. The company has raised ï¿¡850K in additional funding. ACF Investors led the round, including participation from Wren Capital LLP, o2h Ventures, and angel investors.

Quokka Care, a Nashville, TN-based healthcare technology solutions provider advancing the remote patient monitoring (RPM) space, received a strategic growth investment from Ray Guzman and other healthcare investors. The amount of the deal was not disclosed.

Esperto Medical, an Irvine, CA-based healthtech startup specializing in critical care and remote patient monitoring, raised an undisclosed amount in Series A Funding. The round was led by Catalyst Health Ventures and BOLD Capital Partners, with participation from Wavemaker Three-Sixty Health, Free Flow Ventures, Fund@Caltech, and Maverick Ventures.?

Humane Genomics, a NYC-based developer of precision-designed therapies, raised an undisclosed amount in Seed funding. Union Square Ventures led the round.

OpenEvidence, a Cambridge, MA-based provider of an AI copilot for doctors, raised an undisclosed amount in Series A funding at $1 Billion valuation. Sequoia Capital led the round. The company intends to use the funds to train its next generation of medical domain-specialized large language models (LLMs), continue to assemble and grow its team of scientists working at the intersection of LLMs and medicine and forge strategic content partnerships.

Prickly Pear Health, a digital health company based in Phoenix, AR, focuses on brain health during the menopausal transition. The company has raised Pre-Seed funding led by Bayless Ventures and AZ Venture Capital Inc. Other investors included Dr. Alyx Porter Umphrey, a Neurooncologist at Mayo Clinic; Dr. Heidi Jannenga, Co-founder of WebPT; and Ginny Wright, CEO of Audemars Piguet, Americas.

FUNDS

naturalX Health Ventures, a Berlin-based venture capital firm focused on consumer health, closed a €100M fund. Schwabe Group, a global leader in plant-based pharmaceuticals, backs the firm. The fund will focus primarily on Series-A investments while remaining flexible enough to participate in late Seed and Series-B rounds.